Právní předpis byl sestaven k datu 01.10.2015.
Zobrazené znění právního předpisu je účinné od 01.10.2015 do 28.02.2017.
Příloha č. 1 - Seznam č. 1 omamných látek
Příloha č. 2 - Seznam č. 2 omamných látek
Příloha č. 3 - Seznam č. 3 omamných látek
Příloha č. 4 - Seznam č. 4 psychotropních látek
Příloha č. 5 - Seznam č. 5 psychotropních látek
Příloha č. 6 - Seznam č. 6 psychotropních látek
Příloha č. 7 - Seznam č. 7 psychotropních látek
Příloha č. 8 - Seznam č. 8 vybraných přípravků
463
XXXXXXXX XXXXX
xx xxx 18. xxxxxxxx 2013
x xxxxxxxxx xxxxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx §44c xxxx. 1 zákona x. 167/1998 Xx., x návykových látkách x o změně xxxxxxxxx dalších xxxxxx, xx xxxxx zákona x. 273/2013 Xx.:
§1
Xxxx xxxxxxxx stanoví
a) x příloze č. 1 k xxxxxx xxxxxxxx xxxxxx
1. xxxxxxxx látek xxxxxxxxxx xx Xxxxxxx X xxxxx Jednotné úmluvy x omamných látkách1) x
2. xxxxxxx xxxxxxxx xxxxx, x xxxxx xx x důvodu xxxxxxx xxxxxx xxxxxxxxxx xxxxx proto, xx xxxxxxxxxxxxx nebo xxxxxxx xxxxxxxx xxxxxx, xxxxxxxx xxxxxxx zacházení xxx xx xxxxxxx xxxxxxxx x xxxxxxxxx, nebo xx x xxxxxx xxxxxx xxxxx xxxxxxxxxx, xxx léčivé přípravky xxxxxxxxxx xxxx xxxxxx xxxxx xxxx xxxxxxxx x xxxxxxx pouze xx recept nebo xxxxxxx označené modrým xxxxxx směřujícím x xxxxxx dolního xxxx xx xxxxxxx horního xxxx,
(xxxx xxx "xxxxxx x. 1 xxxxxxxx xxxxx"),
x) x příloze č. 2 x xxxxxx xxxxxxxx xxxxxx
1. xxxxxxxx xxxxx xxxxxxxxxx xx Seznamu XX xxxxx Xxxxxxxx xxxxxx x xxxxxxxx xxxxxxx a
2. dalších xxxxxxxx xxxxx, x xxxxx xx z xxxxxx xxxxxxx jejich xxxxxxxxxx xxxxx xxxxx, xx bezprostředně nebo xxxxxxx xxxxxxxx xxxxxx, xxxxx xxxxxxxxxx, xxx xxxxxx xxxxxxxxx obsahující xxxx xxxxxx xxxxx xxxx xxxxxxxx x xxxxxxx xx xxxxxx xxxx xxxxxxx bez xxxxxxxx modrým xxxxxx,
(xxxx xxx "seznam č. 2 xxxxxxxx xxxxx"),
x) x příloze č. 3 x xxxxxx xxxxxxxx xxxxxx
1. xxxxxxxx xxxxx zařazených xx Seznamu IV xxxxx Xxxxxxxx úmluvy x xxxxxxxx xxxxxxx x
2. xxxxxxx omamných xxxxx, u xxxxx xx x xxxxxx xxxxxxx jejich zneužívání xxxxx xxxxx, xx xxxxxxxxxxxxx xxxx nepřímo xxxxxxxx zdraví, xxxxx xxxxxxxxxx, xxx xxxxx x xxxxxxxxx xxxxxxxxxx xxxx omamné látky xxxx používány xxxxx x xxxxxxxx výzkumným, xxxxxxxx a velmi xxxxxxxx xxxxxxxxxxxxx xxxxxx xxxxxxxxx v xxxxxxxx x xxxxxxxxx,
(xxxx xxx "xxxxxx x. 3 xxxxxxxx xxxxx"),
x) x příloze č. 4 x tomuto xxxxxxxx xxxxxx
1. psychotropních xxxxx xxxxxxxxxx xx Xxxxxxx I xxxxx Xxxxxx x psychotropních xxxxxxx2) a
2. xxxxxxx xxxxxxxxxxxxxx xxxxx, x xxxxx je z xxxxxx xxxxxxx jejich xxxxxxxxxx xxxxx xxxxx, xx bezprostředně xxxx xxxxxxx ohrožují xxxxxx, xxxxx zabezpečit, aby xxxxx x xxxxxxxxx xxxxxxxxxx xxxx psychotropní xxxxx xxxx používány xxxxx x xxxxxxxx xxxxxxxxx, xxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxx xxxxxxxxx v xxxxxxxx x zacházení,
(dále xxx "xxxxxx č. 4 psychotropních xxxxx"),
x) x příloze č. 5 x xxxxxx xxxxxxxx xxxxxx
1. xxxxxxxxxxxxxx látek zařazených xx Xxxxxxx II xxxxx Xxxxxx x xxxxxxxxxxxxxx látkách x
2. xxxxxxx xxxxxxxxxxxxxx látek, x xxxxx xx x xxxxxx rozsahu xxxxxx xxxxxxxxxx xxxxx xxxxx, že xxxxxxxxxxxxx xxxx nepřímo xxxxxxxx xxxxxx, xxxxxxxx umožnit xxxxxxxxx xxx xx xxxxxxx povolení x xxxxxxxxx, nebo xx x xxxxxx důvodu xxxxx xxxxxxxxxx, aby xxxxxx přípravky obsahující xxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxx x xxxxxxx xxxxx xx xxxxxx xxxx xxxxxxx xxxxxxxx xxxxxx pruhem xxxxxxxxxx x xxxxxx xxxxxxx xxxx xx xxxxxxx xxxxxxx xxxx,
(xxxx xxx "seznam x. 5 xxxxxxxxxxxxxx xxxxx"),
x) x příloze č. 6 x xxxxxx xxxxxxxx seznam xxxxxxxxxxxxxx xxxxx xxxxxxxxxx xx Xxxxxxx III xxxxx Xxxxxx x xxxxxxxxxxxxxx látkách,
g) x příloze č. 7 k xxxxxx xxxxxxxx xxxxxx
1. psychotropních xxxxx xxxxxxxxxx xx Xxxxxxx IV podle Xxxxxx x xxxxxxxxxxxxxx xxxxxxx x
2. xxxxxxx xxxxxxxxxxxxxx látek, u xxxxx xx x xxxxxx rozsahu jejich xxxxxxxxxx anebo proto, xx xxxxxxxxxxxxx xxxx xxxxxxx xxxxxxxx xxxxxx, xxxxx xxxxxxxxxx, xxx xxxxxx přípravky xxxxxxxxxx xxxx xxxxx xxxx xxxxxxxx x xxxxxxx xx xxxxxx xxxx xxxxxxx xxx xxxxxxxx xxxxxx xxxxxx,
(xxxx xxx "xxxxxx x. 7 xxxxxxxxxxxxxx xxxxx"), x
x) x příloze č. 8 k xxxxxx xxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxx xx Xxxxxxx XXX xxxxx Xxxxxxxx xxxxxx o xxxxxxxx látkách,
(dále xxx "xxxxxx x. 8 xxxxxxxxx přípravků").
§2
Xxxx xxxxxxxx xxxx xxxxxxxx v souladu xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/34/ES xx dne 22. xxxxxx 1998 x xxxxxxx při xxxxxxxxxxx xxxxxxxxx x xxxxxxx xxxxx x xxxxxxxxxxx xxxxxxxx x xxxxxxxx xxx služby xxxxxxxxxx společnosti, x xxxxxxx znění.
§3
Toto xxxxxxxx xxxxxx xxxxxxxxx dnem 1. xxxxx 2014.
Příloha x. 1 x nařízení xxxxx x. 463/2013 Xx.
Xxxxxx x. 1 xxxxxxxx xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx název (XXX) v českém xxxxxx |
Xxxxxxxx xxxxx podle XXXXX |
Xxxxxxxx |
|
Xxxxxxxxx |
(5X,6X,7X)-7-[(2X)-2-xxxxxxxxxxxxx-2-xx]-6-xxxxxxx-17-xxxxxx-4,5-xxxxx- 6,14-ethenomofinan-3-yl-acetán |
|
|
AcelyI-alfa-methylfentanyl |
(RS)-N-[1-(2-fenyI-2-methylethyl)-4-piperidyl]acetanilid |
|
|
AcetyImethadol |
(3RS)-6-(dirnethylamino)-4,4-difenylheptan-3-yl-acetát |
|
|
Alfacetylmethadol |
(3R,6R)-6-(dimethylamino)-4,4-difenylheptan-3-yl-acetát |
|
|
Alfameprodin |
(3RS,4Rs)-3-elhyl-4-fenyl-1-methylpiperidin-4-yl-propanoát |
|
|
Alfarnethadol |
(3R,6R)-6-(dimethylamino)-4,4-difenylheptan-3-ol |
|
|
Alfa-methylfentanyl |
N-{1-[(1RS)-2-fenyl-1-methylethyl]piperidin-4-yl}propananilid |
|
|
Alfa-methylthiofentanyl |
N-{1-[(1RS)-1-methyl-2-(2-thienyl)ethyl]piperidin-4-yl}propananilid |
|
|
AIfaprodin |
(3R,4SR)-4-fenyl-1,3-dimethylpiperidin-4-yI-propanoát |
|
|
Alfentanil |
N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl) xxxxxxxxx-4-xx}-X-xxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxx |
3-xxxxx-4-xxxxx-1-xxxxxxxxxxxxxxx-4-xx-xxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx-1-(4-xxxxxxxxxxxxx)-4-xxxxxxxxxxxxxx-4-xxxxxxxxxx |
|
|
Xxxxxxxxxxx |
xxxxx-1-[2-(xxxxxxxxx)xxxxx]-4-xxxxxxxxxxxxxx-4-xxxxxxxxxx |
|
|
Xxxxxxxxxxxx |
3-(xxxxxxXxxx)-4.5α-xxxxx-17-xxxxxxxxxxxx-7-xx-6α-xx |
|
|
Xxxxxxxxxxxxxxxxxx |
(3X,6X)-6-{xxxxxxxxxxxxx )-4.4-xxxxxxxxxxxxx-3-xx-xxxxxx |
|
|
Xxxx-xxxxxxxxxxxxxxx |
X-{1-[(2XX)-2-xxxxxxxxxxxxxxx]xxxxxxxxx-4-xx}xxxxxxxxxxxx |
|
|
Xxxx-xxxxxxxxxxxxxxxxxxxxx |
X-{1-[(2XX)-2-xxxxxxxxxxxxxxx]-3-xxxxxxxxxxxxxxx-4-xx}xxxxxxxxxxxx |
|
|
Xxxxxxxxxxxx |
(3XX,4XX)-3-xxxxx-4-xxxxX-1-xxxxxxxxxxxxxxx-4-xx-xxxxxxxxx |
|
|
Xxxxxxxxxxxx |
(3X,6X)-6-(xxxxxxxxxxxxx)-4,4-xxxxxxxxxxxxx-3-xx |
|
|
Xxxxxxxxxx |
(3XX,4XX)-4-xxxxx-1,3-xxxxxxxxxxxxxxxxx-4-xx-xxxxxxxxx |
|
|
Xxxxxxxxxx |
2,2-xxxxxxX-4-[4-(2-xxx-3-xxxxxxxxX-2,3-xxxxxxx-1X-xxxxxxxxxxxx-1-xx) xxxxxxxxxx]xxxxxxxxxxx |
|
|
Xxxxxxxxxxxxx |
1-[(3X)-2,2-xxxxxxx-3-xxxxxx-4-xxxxxxxxxxxxxxxxx]xxxxxxxxxx |
|
|
Xxxxxxxxxx |
X-[2-(X-xxxxxxxx-X-xxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxx |
3-(xxxxxxxxxxxx)-1,1-xx(2-xxxxxxx)xxx-1-xx |
|
|
Xxxxxxxxx |
1-(3,3-xxxxxxx-3-xxxxxxxxxx-4-xxxxxxxxxxxxxx-4-xxxxxxxxxxx xxxxxxxx |
|
|
Xxxxxxxxxxx |
xxxxx-1-(3,3-xxxxxxx-3-xxxxxxxxxx)-4-xxxxxxxxxxxxxx-4-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
(5X,6X,7X)-4,5-xxxxx-7-[(2X)-2-xxxxxxxxxxxxx-2-xx]-6-xxxxxxx-17-xxxxxx- 6,14-xxxxxxxxxxxxxx-3-xx |
|
|
Xxxxxxxxxxxxx |
4,5α-xxxxx-17-xxxxxxxxxxxxxx-3,6α-xxxx |
|
|
Xxxxxxxxxxx |
[2-(xxxxxxxxxxxxx)xxxxx)]-2-xxxxxx-2,2-xxxxxxx-xxxxxx |
|
|
Xxxxxxxxxxxx |
6-(xxxxxxxxxxxxxx)-4,4-xxxxxxxxxxxxx-3-xx |
|
|
Xxxxxxxxxxxxxxxxxx |
X,X,1-xxxxxxxxx-3,3-xx(2-xxxxxxx)xxxxxxxxx |
|
|
Xxxxxxxxxx-xxxxxxx |
xxxxx-2,2-xxxxxxx-4-xxxxxxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
|
Xxxxxxxxx |
(6XX)-4,4-xxxxxxx-6-xxxxxxxxxxxxxxxx-3-xx |
|
|
Xxxxxxxxxx |
(6X)-3,4-xxxxxxxxx-17-xxxxxxxxxxxxxx-6β,14-xxxx |
|
|
Xxxxxxx |
xxxxxxxx (1X,2X,3X,5X)-3-xxxxxxx-8-xxxxxx-9-xxxxxxxxxx[3.2.1]xxxxx-2-xxxxxxxxxxx, její xxxxxx x xxxxxxxx, x xxxxxxx je xxxxx xxxxxx ekgonin x xxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X,1-xxxxxxxx-3,3-xxx(2-xxxxxxx)-2-xxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
1-[2-(xxxxxxxxxxxx)xxxxx]-2-(4-xxxxxxxxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx-4-xxxxx-1-[2-(2-xxxxxxxxxxxxx)xxxxx]xxxxxxxxx-4-xxxxxxxxxx |
|
|
Xxxxxxxxx |
4,4-xxxxxxx-6-xxxxxxxxxxxxxxx-3-xx |
|
|
Xxxxxxxxxxx |
X-(1-xxxxxx-2-xxxxxxxxxxxxxxx)xxxxxxxxxxxx |
|
|
Xxxxxxxxx |
(2XX,6X,11X)-3-xxxxxxxx-6,11-xxxxxxxx-1,2,3,4,5,6-xxxxxxxxx-2,6-xxxxxxx- 3-benzazocin-8-ol |
|
|
Fenomorfan |
17-fenethyImorfinan-3-ol |
|
|
Fenoperidin |
ethyl-4-fenyl-1-(3-fenylpropyl)-3-hydroxypiperidin-4-karboxylát |
|
|
Fentanyl |
N-(1-fenethylpiperidin-4-yl)-N-fenylpropanamid |
|
|
Furethidin |
ethyI-4-fenyI-1-[2-(furfuryloxy)ethyl]piperidinn-4-karboxylát |
|
|
Hydrokodon |
4,5α-epoxy-3-methoxy-17-rnethyImorfinan-6-on |
|
|
Hydromorfinol |
4,5α-epoxy-17-methylmorfinan-3,6α,14-triol |
|
|
Hydromorfon |
4,5α-epoxy-3-hydroxy-17-rnethylmorfinan-6-on |
|
|
Hydroxypethidin |
ethyl-4-(3-hydroxyfenyl)-1-rnethylpiperidin-4-karboxylát |
|
|
lsomethadon |
6-(dimethylamino)-4,4-difenyl-5-methylhexan-3-on |
|
|
Karfentanil |
methyl-1-fenethyl-4-(N-fenylpropanamido)piperidin-4-karboxylát |
|
|
Klonitazen |
2-(4-chlorbenzyl)-1-[2-(diethylarnino)ethyl]-5-nitro-1H-benzimidazol |
|
|
Kodoxim |
kyselina 2-{[X-(4,5α-xxxxx-3-xxxxxxx-17-xxxxxxxxxxxxxxx-6-xxxxxx) xxxxx]xxx}xxxxxx |
|
|
Xxxx - xxxx |
Xxxxxx list |
|
|
Kokain |
(1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyklo[3.2.1]oktan-2- karboxylát |
|
|
Koncentrát x makoviny |
Poloprodukt x xxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx makoviny |
|
|
Konopí xxxxxxx x xxxxxxxx |
Xxxxxxx x xxxxxxxx z xxxxxx |
|
|
Xxxxxx pro xxxxxxx xxxxxxx |
xxxxxx xxxxxx x xxxxxxxx léčivých xxxxxxxxx xx xxxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxx |
1-xxxxx-2-[(9X,13X,14X)3-xxxxxxxxxxxxxxx-17-xx]xxxxx-1-xx |
|
|
Xxxxxxxxxxxxx |
(9X,13X,14X)-3-xxxxxxxx-17-xxxxxxxxxxxxxx |
Xxxxxxxxxxxxxx dextromethorfan [(+)-3-xxxxxxx-17- xxxxxxxxxxxxxx] xx vyňat xx xxxxxxx xxxxxxxx xxxxx xxxxxxxxx x xxxx příloze |
|
Levomoramid |
(3R)-2,2-difenyl-3-methyl-4-morfolino-1-(pyrrolidin-1-yl)butan-1-on |
|
|
Levorfanol |
(9R,13R,14R)-17-methylmorfinan-3-ol |
Stereoizomerní xxxxxxxxxxx [(+)-3-xxxxxxx-17- xxxxxxxxxxxxxx] xx xxxxx xx xxxxxxx xxxxxxxx látek uvedených x xxxx xxxxxxx |
|
Xxxxxxxxx |
(2X,6X,11X)-3,6,11-xxxxxxxxx-1,2,3,4,5,6-xxxxxxxxx-2,6-xxxxxxxxx-3- xxxxxxxxx-8-xx |
|
|
Xxxxxxxx |
(6XX)-6-(xxxxxxxxxxxxx)4,4-xxxxxxxxxxxxx-3-xx |
|
|
Xxxxxxxx, xxxxxxxxxxx |
4-(xxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
4,5α-xxxxx-6,17-xxxxxxxxxxxxxx-6-xx-3-xx |
|
|
Xxxxxxxxxxxxxxxxxxx |
4,5-xxxxx-6,17-xxxxxxxxxxxxxxxx-3,6-xxxx |
|
|
Xxxxxxx |
4,5-xxxxx-3-xxxxxxx-5,17-xxxxxxxxxxxxxxxx-6-xx |
|
|
Xxxxxxx, meziprodukt |
2,2-difenyl-3-methyl-4-rnorfolinobutanová xxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
X-(1-xxxxxxxx-3-xxxxxxxxxxxxxxx-4-xx)xxxxxxxxxxxx |
3-Xxxxxxxxxxxxxx |
|
Xxxxxxxxxxxxxxxxxx |
X-{(3XX)-3-xxxxxx-1-[2-(2-xxxxxxx)xxxxx]xxxxxxxxx-4-xx}xxxxxxxxxxxx |
3-xxxxxxxxxxxxxxxxxx |
|
Xxxxxxxxxx |
xxxxx-4-xxxxx-1-(3-xxxxxxxxxxxxxx)xxxxxxxxx-4-xxxxxxxxxx |
|
|
Xxxxxx |
4,5α-xxxxx-17-xxxxxXxxxxxx-7-xx-3,6α-xxxx |
|
|
Xxxxxx methobromid |
4,5α-epoxy-3,6α-dihydroxy-17,17-dimethylmorfin-7-en-17-ium-bromid |
a xxxx xxxxxxxx xxxxxxx se xxxxxxxxxx xxxxxxx xxxxxx xxxxxxxx xxxxxx-X-xxxxx (x xxxxxx-X-xxxxx) |
|
Xxxxxx-X-xxxx |
4,5α -xxxxx-17-xxxxxxxxxxxx-7-xx-3,6α-xxxx-17-xxxx |
|
|
XxxxxxxxXxxxxxx |
4-xxxxx-1-xxxxxxxxxxxxxxx-4-xx-xxxxxxxxx |
XXXX |
|
Xxxxxxx |
3-(xxxxxxxxx)-4,5α-xxxxx-17-xxxxxxxxxxxx-7-xx-6-xx-xxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
4,5α-xxxxx-17-xxxxxxxxxxxx-7-xx-3,6α-xxxx-xxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
4,4-xxxxxxx-6-(xxxxxxxxxxx)xxxxxx-3-xx-xxxxxx |
|
|
Xxxxxxxxxxxxx |
(9X,13X,14X)-xxxxxxxx-3-xx |
|
|
Xxxxxxxxxxx |
6-(xxxxxxxxxxxxx)-4,4-xxxxxxxxxxxx-3-xx |
|
|
Xxxxxxxxx |
4,5α-xxxxxxxxxxx-7-xx-3,6α-xxxX |
|
|
Xxxxxxxxxx |
4,4-xxxxxxx-6-xxxxxxxxxxxxxxx-3-xx |
|
|
Xxxxx |
Xxxxx xxxxxxxxxxxx xxxxxxxxxx přípavků, jejichž xxxxxx xxxxxx xx xxxxx než X4 xxxx XX2 |
|
|
Xxxxxxxx |
4,5α-xxxxx-6-xxxxxxx-17-xxxxxxxxxxxxx-6,8(14)-xxxx-3-xx |
|
|
Xxxxxxxx |
(5X)-4,5-xxxxx-14-xxxxxxx-3-xxxxxxx-17-xxxxxxxxxxxxxx-6-xx |
|
|
Xxxxxxxxx |
(5X)-4,5-xxxxx-3,14-xxxxxxxxx-17-xxxxxxxxxxxxxx-6-xx |
|
|
Xxxxxxxxxxxxxxxxx |
X-(1-xxxxxxxXxxxxxxxxx-4-xx)-4'-xxxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx-1-xxxxxxxx-4-xxxxxxxxxxxxxx-4-xxxxxxxxxx |
XXXXX |
|
Xxxxxxxx |
xxxxx-4-xxxxx-1-xxxxxxxxxxxxxxx-4-xxxxxxxxxx |
|
|
Xxxxxxxx, xxxxxxxxxxx X |
4-xxxxx-1-xxxxxxxxxxxxxxx-1-xxxxxxxxxxx |
|
|
Xxxxxxxx, xxxxxxxxxxx B |
ethyl-4-fenylpiperidin-4-karboxylát |
|
|
Pethidin, xxxxxxxxxxx X |
xxxxxxxx 4-fenyl-1-methylpiperidin-4-karboxylová |
|
|
Piminodin |
ethyl-1-(3-anilinopropyl)-4-fenylpiperidin-4-karboxylát |
|
|
Piritramid |
1'-(3,3-difenyl-3-kyanpropyl-4'-ureido-1,4'-bipiperidin |
|
|
Proheptazin |
4-fenyl-1,3-dimethylazepan-4-yl-propanoát |
|
|
Properidin |
isopropyI-4-fenol-1-methylpiperidin-4-karboxylát |
|
|
Racemethorfan |
(9RS,13RS,14RS)-3-methoxy-17-methylmorfinan |
|
|
Racernoramid |
(3RS)-2,2-dyfenil-3-methyl-4-morfolino-1-(pyrrolidin-1-yl)butan-1-on |
|
|
Racemorfan |
(9RS,13RS,14RS)-17-methylmorfinan-3-ol |
|
|
Rernifentanil |
methyl-3-[4-(N-acetonylanilono)4-(methoxykarbonyl)]piperidino]propanoát |
|
|
Sufentanil |
N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}propananilid |
|
|
Tapentadol |
3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]fenol |
|
|
Thebain |
4,5α-epoxy-3,6-dimethoxy-17-triethylmorfina-6,8-dien |
|
|
Thebakon |
(5R)-4,5-epoxy-3-methoxy-17-methyImorfin-6-en-6-yl-acetát |
|
|
Thiofentanyl |
N-{1-[2-(2-thienyl)ethyl]piperidin-4-yl}propananilid |
|
|
Tilidin |
ethyl-(1RS,2RS)-2-(dimethylamono)-1-fenylcyklohex-3-en-1-karboxylát |
|
|
Trimeperidin |
(RS)-4-fenyl-4-(1,2,5-trimethylpiperidin-4-yl)propanoát |
Včetně xxxxxxx xxxxxxxx látek xxxxxxxxx x tomto xxxxxxx, dále xxxxxx x ethery xxxxxxxx xxxxx xxxxxxxxx x xxxxx xxxxxxx x xxxx omamných xxxxx xxxxxxxxx x xxxxx xxxxxxx xxxxxx xxxx xxxxxxx, xxxxxx x xxxxx xx xxxxx xxxxxxxxx, kdy xxxx xxxx xxxxx xxxxxxxxx.
Xxxxxxx x. 2 x xxxxxxxx xxxxx x. 463/2013 Sb.
Seznam x. 2 omamných xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx xxxxxx |
Xxxxxxxx xxxxx podle XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxxxxxxxxxxx |
4,5α-xxxxx-3-xxxxxxx-17-xxxxxxxxxxxxxx-6α-xx-xxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
(1X,2X)-1-xxxxxx-3-(xxxxxxxxxxxxx)-1-xxxxxxxxxxxx-xxxxxxxxx |
|
|
Xxxxxxxxxxxxx |
4,5α-xxxxx-3-xxxxxxx-17-xxxxxxxxxxxxxx-6α-xx |
|
|
Xxxxxxxxxxx |
4,5α-xxxxx-3-xxxxxx-17-xxxxxxxxxxxx-7-xx-6α-xx |
|
|
Xxxxxxxx |
4,5α-xxxxx-17-xxxxxx-3-(2-xxxxxxxxxxxxxxx)xxxxxx-7-xx-6α-xx |
|
|
Xxxxxx |
4,5α-xxxxx-3-xxxxxxx-17-xxxxxxxxxxxx-7-xx-6α-xx |
|
|
Xxxxxxxxxxx |
4,5α-xxxxx-3-xxxxxxx-17-xxxxxxxxxxxxxx-6α-xx-xxxxxxxxx |
|
|
Xxxxxxxxx |
4,5α-xxxxx-3-xxxxxxx-17-xxxxxxxxxxxx--7-xx-6-xx-xxxxxxxxx |
|
|
Xxxxxxxxx |
4,5α-xxxxx-3-xxxxxxxxxxxxx-7-xx-6α-xx |
|
|
Xxxxxxxx |
X-[(1XX)-1-xxxxxx-2-xxxxxxxxxxxxxxx]-X-(2-xxxxxxx)xxxxxxxxxx |
Xxxxxx izomerů xxxxxxxx xxxxx uvedených x xxxxx xxxxxxx, xxxx xxxx omamných xxxxx xxxxxxxxx v xxxxx xxxxxxx, xxxxxx solí xxxxxxx látek uvedených x xxxxx xxxxxxx xx všech xxxxxxxxx, xxx tyto soli xxxxx existovat.
Xxxxxxx x. 3 x xxxxxxxx xxxxx x. 463/2013 Xx.
Xxxxxx x. 3 xxxxxxxx xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x českém xxxxxx |
Xxxxxxxx název podle XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxx |
4,5α-xxxxx-17-xxxxxxxxxxxxxx-3-xx |
|
|
Xxxxxxx |
[5X,6X,7X,14X)-4,5-xxxxx-7-[(2X)-2-xxxxxxxxxxxxx-2-xx]-6-xxxxxxx- 17-methyl-6,14-ethenomorfinan-3-ol |
|
|
Heroin |
(5R,6S)-4,5-epoxy-17-methylmorfin-7-en-3,6-diyl-diacetát |
|
|
Ketobemidon |
1-[4-(3-hydroxyfenyl)-1-methylpiperidin-4-yl]propan-1-on |
|
|
Konopí |
S výjimkou xxxxxx xxx xxxxxxx xxxxxxx uvedené x xxxxxxx x. 1 |
|
|
Xxxxxxxxxx x xxxxxx |
Xxxxxx solí xxxxxxxx látek xxxxxxxxx x xxxx skupině xx všech xxxxxxxxx, xxx xxxx xxxx xxxxx xxxxxxxxx.
Xxxxxxx x. 4 x nařízení xxxxx x. 463/2013 Xx.
Xxxxxx x. 4 xxxxxxxxxxxxxx xxxxx
|
Xxxxxxxxxxx nechráněný název (XXX) v xxxxxx xxxxxx |
Xxxxx xxxxxxxxxxx nechráněný xxxxx xxxx obecný xxxxx |
Xxxxxxxx xxxxx xxxxx XXXXX |
Xxxxxxxx |
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx)]xxxxxx}xxxxxxxx |
||
|
XX-2201 |
[1-(5-xxxxxxxxxxx)-1X-xxxxx-3-xx](xxxxxxxx-1-xx)xxxxxxxx |
||
|
5-XX1 |
5-(2-xxxxxxxxxxx)xxxxx |
||
|
XXXXXXX |
X-(xxxxxxxxx-1-xx)-1-xxxxxx-1X-xxxxxxx-3-xxxxxxxxxx |
||
|
xx-XXX |
2-xxxxx-1-(4-xxxxxxxxxxxx)xxxxxx-1-xx |
||
|
xx-XXXX |
1-(4-xxxxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
||
|
25X-XXXXx |
2-(4-xxxx-2,5-xxxxxxxxxxxxxx)-X-[(2-xxxxxxxxxxxx)xxxxxx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxx |
XXX |
(2XX)-1-(4-xxxx-2,5-xxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
Xxxxx-Xxxxxxxxx |
1-(8-xxxxxxxxx[1,2x:4,5-x´]xxxxxxx-4-xx)xxxxxx-2-xxxx |
||
|
Xxxxxxx |
2-(xxxxxxxxxxx)-1-[3,4-(xxxxxxxxxxxxx)xxxxx)]xxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxxxxxxxxx |
2X-X |
(4-xxx-2,5-xxxxxxxxxxxxxxxxx)xxxx |
|
|
25X-XXXXx |
2-(4-xxxxx-2,5-xxxxxxxxxxxxxx)-X-[(2-xxxxxxxxxxxx)xxxxxx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
2X-X-2 |
[4-(xxxxxxxxxxxxx)-2,5-xxxxxxxxxxxxxxxxx]xxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
2X-X-7 |
[2,5-xxxxxxxxx-4-(xxxxxxxxXxxxxx)xxxxxxxx]xxxx |
|
|
XX-47,497 |
2-[(1X,3X)-3-xxxxxxxxxxxxxxxxx]-5-(2-xxxxxxxxxxx-2-xx)xxxxx |
||
|
XXX-13 |
(xxxxxxxx-1-xx)[4-(xxxxxxxxx)xxxxxxxx-1-xx]xxxxxxxx |
||
|
XXXX |
1,4-xxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
XXX |
X,X-xxxxxxx-X-[2-(xxxxx-3-xx)xxxxx]xxxx |
|
|
Xxxxxxxxxxxxxxxxxx |
XXX |
(2XX)-1-(2,5-xxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
4,4'-XXXX |
4-xxxxxx-5-(4-xxxxxxxxxxx)-4,5-xxxxxxx-1,3-xxxxxx-2-xxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
XXXX |
3-(1,2-xxxxxxxxxxxxxx)-6,6,9-xxxxxxxxx-7,8,9,10-xxxxxxxxxx-6X-xxxxx[x] xxxxxxx-1-xx |
|
|
3,4-XXXX |
1-(3,4-xxxxxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxx |
XXX |
X[2-(xxxxx-3-xx (ethyl]-N,N-dimethylamin |
|
|
DOC |
1-(4-chlor-2,5-dimethoxyfenyl)propan-2-amin |
||
|
Dimethoxyethylamfetamin |
DOET |
(2RS)-1-(4-ethyl-2,5-dimethoxyfenyl)propan-2-amin |
|
|
DOl |
1-(4-jod-2,5-dimethoxyfenyl)propan-2-amin |
||
|
Eticyklidin |
PCE |
N-ethyl-1-fenylcyklohexylamin |
|
|
Etryptamin |
3-(2-aminobutyl)indol |
||
|
4-FA |
1-(4-fluorfenyl)propan-2-amin |
||
|
5F-AKB48 |
N-(adamantan-1-yl)-1-(5-fluorpentyl)-1H-indazol-3-karboxamid |
||
|
Flefedron |
1-(4-fluorfenyl)-2-(methylamino)propan-1-on |
||
|
4-FMA |
1-(4-fluorfenyl)-N-methylpropan-2-amin |
||
|
3-FMC |
1-(3-fluorfenyl)-2-(methylamino)propan-1-on |
||
|
5FUR-144 |
[1-(5-fluorpentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyklopropyl)methanon |
||
|
251-NBOMe |
2-(4-jod-2,5-dimethoxyfenyl)-N-[(2-methoxyfenyl)methyl]ethanamin |
||
|
JWH-018 |
(naftalen-1-yl)(1-pentyl-1H-indol-3-yl)methanon |
||
|
JWH-073 |
(1-butyl-1H-indol-3-yl)(naftalen-1-yl)methanon |
||
|
JWH-081 |
(4-methoxynaftalen-1-yl)(1 -xxxxxx-1X-xxxxx-3-xx)xxxxxxxx |
||
|
XXX-122 |
(4-xxxxxxxxxxxxxx-1-xx)(1-xxxxxx-1X-xxxxx-3-x)xxxxxxxx |
||
|
XXX-200 |
[1-(2-xxxxxxxxxxxxxx)-1X-xxxxx-3-xx](xxxxxxxx-1-xx)xxxxxxxx |
||
|
XXX-250 |
2-(2-xxxxxxxxxxxx)-1-(1-xxxxxx-1X-xxxxx-3-xx)xxxxx-1-xx |
||
|
XXX-398 |
(4-xxxxxxxxxxxxx-1-xx)(1-xxxxxx-1X-xxxxx-3-xx)xxxxxxxx |
||
|
Xxxxxxxx |
(2X)-2-xxxxx-1-xxxxxxxxxxx-1-xx |
||
|
(+)-Xxxxxxxx |
XXX, XXX-25 |
(+)-8β-(3,3-xxxxxxxxxxxxxx)-6-xxxxxx-9,10-xxxxxxxxxxxxxxxx |
|
|
4-Xxxxxxxxxxxx |
(2XX)-1-(4-xxxxxxxxxxx)xxxxxx-2-xxxx |
||
|
XXXX |
1-xxxxxx-4-xxxxxxxxxxxxxxx |
||
|
xXXX |
1-(3-xxxxxxxxxx)xxxxxxxxx |
||
|
XXXX |
5,6-(xxxxxxxxxxxxx)xxxxx-2-xxxx |
||
|
XXXX |
1-[3,4-(xxxxxxxxxxxxx)xxxxx]-2-(xxxxxxxxxx-1-xx)xxxxxx-1-xx |
||
|
3-XXX |
2-(xxxxxxxxxx)-1-(3-xxxxxxxxxxx)xxxxxx-1-xx |
||
|
4-XXX |
2-(xxxxxxxxxx)-1-(4-xxxxxxxxxxx)-xxxxxx-1-xx |
||
|
Xxxxxxxx |
2-(xxxxxxxxxxx)-1-(4-xxxxxxxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxx |
3,4,5-xxxxxxxxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxx |
Xxxxxxx |
(2XX)-1-xxxxx-2-(xxxxxxxxxxx)xxxxxx-1-xx |
|
|
3-XXX |
2-(xxxxxxxxxxx(-1-(3-xxxxxXxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXXX |
(2XX)-1-[5-xxxxxxx-3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxxxx |
(±)-5-xxxxx-4-xxxxxx-4,5-xxxxxxxxxxxxx-2-xxxxx |
||
|
Xxxxxxxxxxxxxxxxxx |
XXXX |
(2XX)-X-xxxxxx-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
3-XxX-XXX |
1-[1-(3-xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxxxxx |
||
|
xxxxxxxxxxxxx |
2-(xxxxxxxxxx)-2-(3-xxxxxxxxxxxx)xxxxxxxxxxxx |
||
|
Xxxxxxxx |
2-(xxxxxxxxxxx)-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-1-xx |
||
|
XX-45 |
1-xxxxxxxxxx-4-(1,2-xxxxxxxxxxxx)-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxx |
4-XXX |
(2XX)-1-[4-(xxxxxXxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxx |
1-(xxxxxxxx-2-xx)-2-(xxxxxxxxxx-1-xx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxx |
XXX, MDEA |
(2RS)-N-ethyl-1-[3,4-(methylendioxy)fenyllpropan-2-amin |
|
|
Hydroxytenamfetamin |
(2RS)-N-hydroxy-1-[3,4-(methylendioxy)fenyl|propan-2-amin |
||
|
Paraliexyl |
3-hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ol |
||
|
pentedron |
1-fenyl-2-(methylainino)pentan-1-on |
||
|
pFPP |
1-(4-fluorfenyl)piperazin |
||
|
Methoxyamfetamin |
PMA |
(2RS)-1-(4-methoxyfenyl)propan-2-amin |
|
|
Methoxymetamfetamin |
PMMA |
1-(4-methoxyfenyl)-N-methylpropan-2-amin |
|
|
Psilocybin |
3-[2-(dimethylamino)ethyl]-1H-indol-4-yl-dihydrogen-fosfát |
||
|
Psilocin |
Psilotsin |
3-[2-(dimethylamino)ethyl]-1H-indol-4-ol |
|
|
Rolicyklidin |
PHP, XXXX |
1-(1-xxxxxxxxxxxxxxx)xxxxxxxxxx |
|
|
α-XXX |
1-xxxxx-2-(xxxxxxxxxx-1-xx)-1-xxxxxx-1-xx |
||
|
Xxxxxxxxxx A |
methyl-(2RS,4aR,6aR,7R,9RS,10aRS,10bR)-9-acetoxy-2-(furan-3-yl)-6a, 10b-dimethyl-4,10-dioxododekahydro-1H-benzo[f]isochromen-7-karboxylát |
||
|
Dimethoxymetamfetamin |
STP, XXX |
(2XX)-1-(2,5-xxxxxxxxx-4-xxxxxxxxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxx |
XXX |
(2XX)-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxx |
XXX |
1-[1-(2-xxxxxxx)xxxxxxxxxx]xxxxxxxxx |
|
|
XXXXX |
1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXX |
Δ6x(10x)-,Δ6x(7)-,Δ7-,Δ8-,Δ10-,Δ9(11)-xxxxxxxxxxxxxxxxxxxx x xxxxxx xxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
XXX |
(2XX)-1-(3,4,5-xxxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxxxxxxxxx-2 |
XXX-2 |
(2XX)-1-(2,4,5-xxxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
XX-144 |
(1-xxxxxx-1X-xxxxx-3-xx)-(2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx |
Xxxxxx stereaizomerů psychotropních xxxxx, xx na xxxxxxxx xxxxxxx, xxxxxxxxx x xxxxx seznamu xx xxxxx xxxxxxxxx, xxx xxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx podle xxxxxxxxxx xxxxxxxxxx xxxxxxxx x solí xxxxxxxxxxxxxx xxxxx xxxxxxxxx v xxxxx seznamu ve xxxxx xxxxxxxxx, xxx xxxxx xxxxxxxxx.
Xxxxxxx x. 5 x xxxxxxxx xxxxx x. 463/2013 Sb.
Seznam x. 5 psychotropních xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) v xxxxxx xxxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxxx obecný xxxxx |
Xxxxxxxx název xxxxx XXXXX |
Xxxxxxxx |
|
Xxxxxxxxx |
(2XX)-1-xxxxxxxxxxx-2-xxxx |
||
|
Xxxxxxxxxx |
xxxxxxxx 7-[(10,11-xxxxxxx-5X-xxxxxxx[x,x][7]xxxxxxx-5-xx) amino]heptanová |
||
|
Buprenofin |
(2S)-2-[(5R,6R,7R,14S)-17-(cyklopropylmethyl)-4,5α-epoxy-3- xxxxxxx-6-xxxxxxx-6α,14-xxxxxxxxxxxxxx-7x-xx]-3,3-xxxxxxxx butan-2-ol |
||
|
Bromdimethoxyfenethyl xxxx |
2X-X |
(4-xxxx-2,5-xxxxxxxxxxxxxxxxx)xxxx |
|
|
Xxxxxxxxxxxx |
(2X)-1-xxxxxxxxxxx-2-xxxx |
||
|
Xxxxxxxxxxx |
XXX |
1-(1-xxxxxxxxxxxxxxx)xxxxxxxxx |
|
|
Xxxxxxxxx |
7-(2-{[(2XX)-1-xxxxxxxxxxx-2-xx]xxxxx}xxxxx)-1,3-xxxxxxxx-7X- xxxxx-2,6-xxxx |
||
|
Xxxxxxxxxxx |
2-xxxxX-3-xxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxxx |
5-(2-xxxxxxxxxx)-1-xxxxxx-7-xxxxx-1X-1,4-xxxxxxxxxxxxx-2(3X)-xx |
||
|
XXX |
xxxxxxxx 4-xxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxx |
(2XX)-1-xxxxxxxxxxx-2-xxxx |
||
|
Xxxxxxxxxxxxxxx |
(2XX)-1-xxxxx-X-xxxxxxxxxxxx-2-xxxx |
||
|
Xxxxxxxxxxx |
3-(2-xxxxxxxxxx)-2-xxxxxx-1,2-xxxxxxxxxxxxxxxxx-4(3X)-xx |
||
|
Xxxxxxxxxx |
2-xxxxxxx-3-(2-xxxxxxxxxxx)-1,2-xxxxxxxxxxxxxxxxx-4(3X)-xx |
||
|
Xxxxxxxxxxxx |
(2X)-1-xxxxx-X-xxxxxxxxxxxx-2-xxxx |
||
|
Xxxxxxxxxxxx xxxxxxxxx |
(2XX)-1-xxxxx-X-xxxxxxxxxxxx-2-xxxx |
||
|
Xxxxxxxxxxxxx |
xxxxxx-(2XX)-2-xxxxx-2-[(2XX)-xxxxxxxxx-2-xx]xxxxxx |
||
|
Xxxxxxxxxxxx |
xxxxxxxx 5-xxxxx-5-(1-xxxxxxxxxxx)xxxxxxxxxxx |
||
|
Xxxxxxxxxx |
xxxxx-9-XXX |
Δ9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxx xxxxxxxxxxxxx |
xxxx. (-)-xxxxx-Δ9-XXX |
|
Xxxxxxxx |
(2XX)-1-xxxxx-1-xxxxxxx-3-[4-(2-xxxxxxxxxxxxxxx)xxxxxxxxx-1-xx] xxxxxx-2xx |
Xxxxxx xxxx xxxxx xxxxxxxxx v xxxx xxxxxxx ve všech xxxxxxxxx, xxx existence xxxxxxxx xxxx je xxxxx.
Příloha x. 6 x nařízení xxxxx x. 463/2013 Sb.
Seznam x. 6 xxxxxxxxxxxxxx xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x českém xxxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxxx obecný xxxxx |
Xxxxxxxx název podle XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxxx |
xxxxxxxx 5-ethyl-5-isopentylbarbiturová |
||
|
Butalbital |
kyselina 5-allyl-5-isobutylbarbiturová |
||
|
Cyklobarbital |
kyselina 5-(1-xxxxxxxx-1-xx-1-xx)-5-xxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxx |
(3XX)-3-xxxxx-3-xxxxxxxxxxxxxx-2,6-xxxx |
||
|
Xxxxxx |
(+)-xxxxxxxxxxxxxxxx |
(1X,2X)-2-xxxxx-1-xxxxxxxxxxx-1-xx |
|
|
Xxxxxxxxxxx |
(2X,6X,11X)-6,11-xxxxxxxx-3-(3-xxxxxxxxx-2-xx-1-xx)-1,2,3,4,5,6- xxxxxxxxx-2,6-xxxxxxx-3-xxxxxxxxxx-8-xx |
||
|
Xxxxxxxxxxxxx |
xxxxxxxx 5-xxxxx-5[(1XX)-1-xxxxxxxxxxx]xxxxxxxxxxx |
Xxxxxx xxxx xxxxx uvedených x této xxxxxxx xx xxxxx xxxxxxxxx, xxx xxxxxxxxx takových xxxx xx xxxxx.
Xxxxxxx x. 7 x nařízení vlády x. 463/2013 Sb.
Seznam x. 7 xxxxxxxxxxxxxx xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x českém xxxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx nebo xxxxxx xxxxx |
Xxxxxxxx xxxxx podle XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxxxx |
5,5-xxxxxxxxxxxxxxxxxx xxxxxxxx |
||
|
Xxxxxxxxxx |
8-xxxxx-6-xxxxx-1-xxxxxx-4X.[1,2,4]xxxxxxxx[4,3-x][1,4]xxxxxxxxxxxxx |
||
|
Xxxxxxxxxx |
2-(xxxxxxxxxxxx)-1-xxxxxxxxxxx-1-xx |
||
|
Xxxxxxxx |
5-xxxxx-4,5-xxxxxxxxxxxxx-2-xxxx |
||
|
Xxxxxxxx |
5,5-xxxxxxxxxxxxxxxxxx xxxxxxxx |
||
|
Xxxxxxxxxxx |
(+)-X-xxxxxx-X-(2-xxxxx-1-xxxxxxxxxxx)-X-xxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
1-xxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxx |
7-xxxx-5.(2-xxxxxxx)-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxx |
2-xxxx-4-(2-xxxxxxxxxx)-9-xxxxxx-6X-xxxxxx[3,2-x][1,2,4]xxxxxxxx[4,3-x]xxxxxxxx |
||
|
Xxxxxxxxxxxx |
5-xxxxx-5-xxxxxxxxxxxxxxxx xxxxxxxx |
||
|
Xxxxxxxxxxx |
7-xxxxx-5-(2-xxxxxxxxxx)-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxx |
7-xxxxx-5-xxxxx-1-xxxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxx-2xx |
||
|
Xxxxxxxxx |
8-xxxxx-6-xxxxx-4X-[1,2,4]xxxxxxxx[4,3-x][1,4]xxxxxxxxxxxxx |
||
|
Xxxxxxxxx |
X-(1-xxxxxxxxxxxxxxxxxx)xxxxxxxx |
||
|
Xxxxxxxxxxxxx |
1-xxxxx-3-xxxxxxxxx-1-xx-4-xx-3-xx |
||
|
Xxxxxxxxxxxxxx |
(±)-2-(xxxxxxxxxx)-1-xxxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
xxxxx-7-xxxxx-5-(2-xxxxxxxxxx)-2-xxx-2,3-xxxxxxx-1X-1,4-xxxxxxxxxxxxx-3- karboxylát |
||
|
Fendimetrazin |
(2S,3S)-2-fenyl-3,4-dimethylmorfolin |
||
|
Fenkamfamin |
(±)-2-(ethylamino)-3-fenylbicyklo[2.2.1]heptan |
||
|
Fenobarbrial |
5-ethyl-5-fenylbarbiturová kyselina |
||
|
Fenproprex |
(±)-1-fenyl-2-[(2-kyanethyl)amino]propan |
||
|
Fentemin |
2-fenyl-1,1-dimethylethylamin |
||
|
FIudiazepam |
7-chlor-5-(2-fluorfenyl)-1-methyl-1,3-dihydro-2G-1,4-benzodiazepin-2-on |
||
|
FIurrazepam |
7-chlor-2-[2-(diethylamino)ethyl]-5-(2-fluorfenyl)-1,3-dihydro-2H-1,4-bezodiazepin- 2-xx |
||
|
Xxxxxxxxx |
7-xxxxx-5-xxxxx-1-(2,2,2-xxxxxxxxxxxxx)-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxxx |
10-xxxx-11x-(2-xxxxxxxxxx)-2,3,7,11x-xxxxxxxxxxxxxxxxx[3,2-x][1,4]xxxxxxxxxxxxx -6(5H)-on |
||
|
Chlordiazeproxid |
7-chlor-5-fenyl-2-(methylamono)-3H-1,4-benzodiazepin-4-oxid |
||
|
Kamazepam |
7-chIor-5-fenyl-1-methyl-2-oxo-1,3-dihydro-2H-1,4-benzodiazepin-3-yl-dimethyl karbamát |
||
|
Ketamin |
(2RS)-2-(2-chlorfenyl)-2-(methylamino)cyklohexan-1-on |
||
|
Ketazolam |
11-chlor-12b-fenyl-2,8-dimethyl-8,12b-dihydro-4H-[1,3]oxazino[3,2-d][1,4] xxxxxxxxxxxx-4,7(6X)-xxxx |
||
|
Xxxxxxxx |
7-xxxxx-5-xxxxx-1-xxxxxx-1X-1,5-xxxxxxxxxxxx-2,4(3X,5X]-xxxx |
||
|
Xxxxxxxxxx |
5-{2-xxxxxxxxxX}-7-xxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxx |
7-xxxxx-5-xxxxx-2-xxx--2,3-xxxxxxx-1X-1,4-xxxxxxxxxxxxx-3-xxxxxxxxxxx xxxxxxxx |
||
|
Xxxxxxxxxxx |
5-(2-xxxxxxxxxx)-7-xxxxx-1-xxxxxx-1,3-xxxxxxx-2X-xxxxxx[2,3-x][1,4]xxxxxxxx-2-xx |
||
|
Xxxxxxxxxx |
10-xxxxx-11x-(2-xxxxxxxxxx)-2,3,7,11x-xxxxxxxxxxxxxxxxx[3,2-x][1,4] benzodiazepin-6(5H)-on |
||
|
Lefetamin |
SPA |
(-)-1-(dimethylamono)-1,2-difenylethan |
|
|
Loprazolam |
3-(2-chlorfenyl)-2-[(4-methylpiperazin-1-yl)methyl]-8-nitro-2,4-dihydro-1H- xxxxxxxx[1,2-x][1,4]xxxxxxxxxxxxx-1-xx |
||
|
Xxxxxxxxx |
7-xxxxx-5-(2-xxxxxxxxxx)-3-xxxxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxxxx |
7-xxxxx-5-(2-xxxxxxxxxx)-3-xxxxxxx-1-xxxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2 -xx |
||
|
Xxxxxxxx |
5-(4-xxxxxxxxxx)-2,5-xxxxxxx-3X-xxxxxxx[2,1-α]-xxxxxxxx-5-xx |
||
|
Xxxxxxxxx |
7-xxxxx-5-xxxxx-1-xxxxxx-2,3-xxxxxxx-1X-1,4-xxxxxxxxxxxxx |
||
|
Xxxxxxxxx |
(±)-2-[(3-xxxxxxxxxxx)xxxxx]-1-xxxxxxxxxxx |
||
|
Xxxxxxxxxx |
2-xxxxxx-2-xxxxxxxxxxxx-1,3-xxxx-xxxxxxxxxx |
||
|
Xxxxxxxx |
X-(xxxxxxxxxxxxxx)-3-(2-xxxxx-1-xxxxxxxxxxx)xxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxx |
5-xxxxx-5-xxxxx-1-xxxxxxxxxxxxxxxxx xxxxxxxx |
||
|
Xxxxxxxxxxx |
3,3-xxxxxxx-5-xxxxxxxxxxxxxxx-2,4-xxxx |
||
|
Xxxxxxxxx |
8-xxxxx-6-(2-xxxxxxxxxx)-1-xxxxxx-4X-xxxxxxxx[1,5-α][1,4]xxxxxxxxxxxx |
||
|
Xxxxxxxxxxx |
5-xxxxX-1-xxxxxx-7-xxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxx |
5-xxxxx-7-xxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxx |
7-xxxxx-5-xxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxx |
7-xxxxx-5-xxxxx-3-xxxxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxx |
10-xxxxx-11x-xxxxx-2-xxxxxx-2,3,7,11x-xxxxxxxxxxxxxxxxx[3,2-x][1,4] xxxxxxxxxxxxx-6(5X)-xx |
||
|
Xxxxxxx |
5-xxxxX-2-xxxxx-1,3 -xxxxxxxxxx-4-xx |
||
|
Xxxxxxxxx |
7-xxxxxx-4-xxxxx-1-(xxxx-2-xx)-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxx |
xxxxxxX(2-xxxxxxxxx)xxxxxxxx |
||
|
Xxxxxxxx |
7-xxxxx-1-(xxxxxxxxxxxxxxxxx)-5-xxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxxx |
(±)-1-(4-xxxxxxxxxxx)-2-(xxxxxxxxxx-1-xx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxx |
5-xxxxx-5-(1-xxxxxxxxxxxxxxxx)xxxxxxxxxxx xxxxxxxx |
||
|
Xxxxxxxxx |
(XX)-7-xxxxx-5-xxxxx-3-xxxxxxx-1-xxxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxx |
7-xxxxx-5-(xxxxxxxx-1-xx-1-xx)-1-xxxxxx-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxx-2-xx |
||
|
Xxxxxxxxxx |
8-xxxxx-6-(2-xxxxxxxxxx)-1-xxxxxx-4X-[1,2,4]xxxxxxxx[4,3-α][1,4]xxxxxxxxxxxxx |
||
|
Xxxxxxxxxx |
5-(1-xxxxxxxxxxx)-5-xxxxxxxxxxxxxxxx xxxxxxxx |
||
|
Xxxxxxxx |
X,X,6-xxxxxxxxx-2-(4-xxxxxxxxxxx)xxxxxxxx[1,2-α]xxxxxxx-3-xxxxxxxx |
Xxxxxx solí xxxxx xxxxxxxxx v xxxx xxxxxxx xx xxxxx xxxxxxxxx, xxx xxxxxxxxx xxxxxxxx xxxx xx xxxxx.
Xxxxxxx č. 8 x nařízení xxxxx x. 463/2013 Sb.
Seznam x. 8 xxxxxxxxx xxxxxxxxx
|
Xxxxxxxxx xxxxxxxxxx: |
Xxxxxxxx: |
||
|
1) |
xxxxx x xxxxxxxx xxxxx: xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxXxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx |
Xxxxx obsahovat xxxxx nebo xxxx xxxxxxx xxxxx (xxxxxxx xxxx omamných) x xxxxxxxx xxxxxx xxxxx |
|
|
x) |
x xxxxx tabletě, xxxxxxx, xxxxxx, xxxxx, příp. x xxxx xxxxxx xxxxx xxxxx xxxxxxxxxx 100 xx, |
||
|
x) |
x xxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 2,5 % |
||
|
2) |
xxxxxxxxx |
x) |
Xxxxxxxx difenoxinu xxxxx xxxxxxxxxx v xxxxx xxxxxxx, xxxxxxx, ampuli, xxxxx, příp. v xxxx xxxxxx xxxxx 0,5 mg. |
|
b) |
Množství atropin-sulfátu xxxx byt xxxxxxx 5 % x xxxxxxxx xxxxxxxxxxxx v xxxxx xxxxxxx, xxxxxx, xxxxxx, čípku, xxxx. xxxx lékové xxxxx. |
||
|
3) |
xxxxxxxxxxx |
x) |
Xxxxxxxx xxxxxxxxxxxx xxxxx xxxxxxxxxx x jedné xxxxxxx, xxxxxxx, xxxxxx, xxxxx, xxxx. x jiné xxxxxx formě 2,5 xx. |
|
x) |
Xxxxxxxx atropin-sulfátu musí xxx xxxxxxx 1 % k množství xxxxxxxxxxxx x jedné xxxxxxx, tobolce, xxxxxx, xxxxx, popř. x xxxx xxxxxx formě. |
||
|
4) |
dextroprapotyfen |
Množství xxxxxxxxxxxxxxxxx |
|
|
x) |
xxxxx xxxxxxxxxx 135 xx x xxxxx xxxxxxx, xxxxxxx, xxxxxx, xxxxx, xxxx. x xxxx xxxxxx xxxxx. |
||
|
x) |
x xxxxxxx nesmí být xxxxxxxxxxx xxxxx xxx 2,5 %. |
||
|
Xxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxx. |
|||
|
5) |
xxxxxx |
Xxxxxxxx xxxxxxx nesmí xxxxxxxxxx 0,1 % xxxxxxx. |
|
|
6) |
xxxxx xxxx xxxxxx |
x) |
Xxxxxxxx xxxxxxx xxxxx xxxxxxxxxx 0,2 %. |
|
x) |
Xxxx xxxxx xxxxxxxxx jednu xxxx xxxx dalších látek (xxxxxxx však xxxxxxxx). |
||
|
Xxxxxx xxxxx x xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxx xxxxxxx xxxx x xxxxxxx xxxxxxxx, xxx ohrozila xxxxxxx xxxxxx |
|||
|
7) |
xxxxxxxxxxxxx xxxxxx s xxxxx |
x) |
Xxxxxxxx xxxx x xxxxxx nesmí být xxxxx xxx 10 %. |
|
x) |
Xxxxxxxx xxxxxxxxxxxxxxx kořene xxxxx xxx xxxxx xxx 10 %. |
||
|
x} |
Xxxxxxxx xxxxx nebo více xxxxxxx látek (nikoliv xxxx ornamných) nesmí xxx nižší než 80%. |
||
|
8) |
xxxxxxxxx |
x) |
Xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxx 100 xx x jedné tabletě, xxxxxxx, ampuli, xxxxx, xxxx. x xxxx Xxxxxx xxxxx. |
|
x) |
Xxxxxxxxx xxxxxxxxxxxxxx x xxxxxxxxx xxxx xxx xxxxxxx stejné xxxx xxxxx xxx xxxxxxxxx. |
||
Xxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxx xxxxxx xx vyšší xxx D4 nebo XX2.
Xxxxxx předpis x. 463/2013 Xx. nabyl xxxxxxxxx xxxx 1.1.2014.
Xx xxxxx xxxxxx xxxxxxxx xxxxxxxx jsou xxxxxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxx x.:
243/2015 Xx., kterým xx xxxx xxxxxxxx xxxxx x. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx xxxxx
x xxxxxxxxx xx 1.10.2015
46/2017 Xx., xxxxxx xx xxxx xxxxxxxx vlády č. 463/2013 Sb., x xxxxxxxxx návykových xxxxx, xx znění nařízení xxxxx x. 243/2015 Xx.
x xxxxxxxxx xx 1.3.2017 s xxxxxxxx xxxxxxxxx ustanovení, která xxxxxxxx účinnosti 1.5.2017
30/2018 Xx., xxxxxx se xxxx nařízení vlády x. 463/2013 Xx., x seznamech xxxxxxxxxx xxxxx, xx znění xxxxxxxxxx předpisů
s účinností xx 8.3.2018
242/2018 Xx., xxxxxx xx mění xxxxxxxx vlády č. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx xxxxx, xx znění xxxxxxxxxx xxxxxxxx
x xxxxxxxxx od 25.10.2018
184/2021 Sb., kterým xx mění xxxxxxxx xxxxx x. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx xxxxx, xx xxxxx xxxxxxxxxx xxxxxxxx
x xxxxxxxxx od 3.6.2021
159/2022 Xx., xxxxxx xx xxxx xxxxxxxx xxxxx x. 463/2013 Xx., x seznamech xxxxxxxxxx xxxxx, xx znění xxxxxxxxxx xxxxxxxx
x xxxxxxxxx xx 1.7.2022
228/2023 Sb., xxxxxx se xxxx xxxxxxxx xxxxx č. 463/2013 Sb., o xxxxxxxxx xxxxxxxxxx xxxxx, xx xxxxx xxxxxxxxxx xxxxxxxx
x účinností xx 1.8.2023
52/2024 Xx., xxxxxx xx xxxx nařízení xxxxx x. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx látek, xx xxxxx pozdějších xxxxxxxx
x xxxxxxxxx xx 6.3.2024 x 1.1.2025
176/2023 Xx., xxxxxx xx mění xxxxxxxx vlády č. 463/2013 Sb., x xxxxxxxxx xxxxxxxxxx xxxxx, xx znění pozdějších xxxxxxxx
x xxxxxxxxx xx 1.7.2024 x 1.1.2025
419/2024 Xx., kterým xx xxxx xxxxxxxx xxxxx x. 463/2013 Sb., x xxxxxxxxx xxxxxxxxxx xxxxx, xx znění xxxxxxxxxx xxxxxxxx
x účinností xx 1.1.2025 a 1.4.2025
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx právního předpisu.
1) Xxxxxxxx xxxxxx x xxxxxxxx látkách, xxxxxxxxx xxx č. 47/1965 Sb., xx xxxxx Protokolu x xxxxxxx Xxxxxxxx xxxxxx x xxxxxxxx xxxxxxx, vyhlášeného xxx č. 458/1991 Sb.
2) Xxxxxx x xxxxxxxxxxxxxx látkách, xxxxxxxxx xxx č. 62/1989 Sb.